I now have comprehensive information from multiple authoritative textbooks. Let me compile the complete answer.
Treatment of Rheumatic Fever and Rheumatic Heart Disease
Acute Rheumatic Fever (ARF)
1. Eradication of Group A Streptococcus (Primary Step)
Immediate eradication of GAS is standard practice even before throat culture results are available.
Drug of choice:
- Benzathine penicillin G (BPG) IM - single dose
-
27 kg (60 lb): 1.2 million units IM
- <27 kg: 600,000 units IM
Alternatives (oral, less effective):
- Penicillin V 250 mg twice daily x 10 days
- Amoxicillin 50 mg/kg once daily (max 1 g) x 10 days
- Azithromycin 250 mg daily (for penicillin-allergic patients)
- Erythromycin 40 mg/kg/day (max 1 g/day) divided 2-4 doses x 10 days
Goldman-Cecil Medicine, 2-Volume Set
2. Anti-inflammatory Therapy
For Arthritis and Fever
Arthritis and fever almost always respond to NSAIDs within hours - if not within 3 days, reconsider the diagnosis.
- Aspirin - first-line; 80-100 mg/kg/day in children (4-8 g/day in adults), in divided doses
- Naproxen 10-20 mg/kg/day divided twice daily - used with success in small studies as an alternative
- NSAIDs should continue for 1-2 weeks until ALL symptoms have resolved (not just joint symptoms)
Goldman-Cecil Medicine; Firestein & Kelley's Textbook of Rheumatology
For Carditis (Severe)
- Prednisone 1-2 mg/kg/day (max 80 mg/day, once daily or divided) is the glucocorticoid of choice
- After 2-3 weeks, taper by 20-25% weekly
- The 2020 Australian guidelines list glucocorticoids as optional for very severe carditis; high-quality evidence is still limited
- IV methylprednisolone is recommended by WHO and NZ/Australian guidelines in life-threatening situations
- After stopping glucocorticoids, resume NSAIDs to prevent rebound fever and joint symptoms
- IVIG was not shown to alter the natural history of ARF and is NOT recommended
Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set
For Heart Failure (due to carditis)
- Diuretics
- Angiotensin receptor blockers (ARBs)
- Fluid restriction and bed rest
- Beta-blockers are not currently recommended for HF due to acute carditis
- Valve surgery is rarely needed in acute ARF, but can be helpful in cases of acute valve leaflet rupture
For Sydenham's Chorea
- Usually resolves within weeks to months without treatment
- Valproic acid or carbamazepine can be used for severe or persistent cases
- Haloperidol (low dose) has also been used in refractory chorea
3. Bed Rest
- Strict bed rest is no longer universally recommended
- Normalization of ESR and CRP is used as a practical guide for return to exercise
Secondary Prophylaxis (Preventing Recurrence)
This is the most important long-term intervention. Since streptococcal pharyngitis is often asymptomatic, prevention requires continuous antimicrobial prophylaxis rather than treating only symptomatic episodes.
BPG reduces new streptococcal pharyngitis by 71-91% and new ARF episodes by 87-96%.
Drug of Choice:
| Regimen | Dose | Route | Frequency |
|---|
| Benzathine penicillin G (preferred) | 1.2 million units (>27 kg); 600,000 units (<27 kg) | IM | Every 4 weeks (every 3 weeks for high-risk patients) |
| Penicillin V | 250 mg | Oral | Twice daily |
| Erythromycin (penicillin-allergic) | 400 mg (adults); 40 mg/kg/day (children, max 1 g/day) | Oral | Twice daily |
IM BPG is more effective than oral penicillin for preventing recurrences.
Duration of Secondary Prophylaxis:
| Category | Duration |
|---|
| ARF without carditis | 5 years OR until age 21 (whichever is longer) |
| ARF with carditis, no residual valve disease | 10 years OR until age 21 (whichever is longer) |
| ARF with carditis + persistent valve disease | 10 years OR until age 40 (whichever is longer), sometimes lifelong |
| Severe valvular disease / after valve surgery | Lifelong |
Firestein & Kelley's Textbook of Rheumatology; Goldman-Cecil Medicine
Rheumatic Heart Disease (RHD)
RHD is almost exclusively a valvular disease. The mitral valve is affected in nearly 100% of cases; the aortic valve in 20-30%. Mitral regurgitation is most common; mitral stenosis is the most common cause of acquired mitral stenosis worldwide.
Medical Management:
- Continue secondary prophylaxis (BPG as above) - this is the cornerstone
- Echocardiography for diagnosis, follow-up, and surveillance
- Atrial fibrillation (a frequent complication) - rate control and anticoagulation (warfarin preferred over NOACs in RHD-associated AF)
- Heart failure - standard HF therapy (diuretics, ACE inhibitors/ARBs, beta-blockers)
- Infective endocarditis prophylaxis - per current guidelines for high-risk valve lesions
Interventional/Surgical Management:
Indicated for severe or symptomatic valvular disease:
- Percutaneous mitral balloon valvotomy (PMBV) - procedure of choice for suitable mitral stenosis (pliable, non-calcified valve, no significant MR)
- Mitral valve repair or replacement - for severe mitral regurgitation or calcified/unsuitable stenotic valves
- Aortic valve repair or replacement - for significant aortic regurgitation or stenosis
- Catheter-based interventions are the first consideration per current valvular disease guidelines
Goldman-Cecil Medicine; Firestein & Kelley's Textbook of Rheumatology; Sabiston Textbook of Surgery
Summary Table: ARF Treatment at a Glance
| Problem | Treatment |
|---|
| GAS eradication | Benzathine penicillin G IM (single dose) |
| Arthritis / Fever | Aspirin 80-100 mg/kg/day or Naproxen |
| Severe carditis | Prednisone 1-2 mg/kg/day; IV methylprednisolone if life-threatening |
| Heart failure | Diuretics, ARBs, fluid restriction |
| Chorea | Usually self-limiting; valproate/haloperidol if severe |
| Secondary prophylaxis | Monthly BPG IM (every 3 weeks for high-risk); duration per category |
| Valvular disease | PMBV, valve repair/replacement per severity |
Recent evidence note: A 2024 Cochrane systematic review (
PMID 39312290) on long-term antibiotic prophylaxis for preventing RHD progression confirms BPG remains the cornerstone of secondary prevention, consistent with current guidelines. A separate 2024 meta-analysis (
PMID 39542478) found adherence to secondary prophylaxis remains a major challenge globally, highlighting the need for patient education and structured follow-up programs.